Clinical trials: Febrile Neutropenia (FN), active
Bloodstream Infection, Gram Negative Infections
Antibiotic Duration and Outcomes in High-Risk Febrile Neutropenia Patients
The goal of this clinical trial is to learn if a personalized duration of antibiotic therapy, based on clinical stability, is as effective as a standard duration of at least 10 days in hospitalized patients with hematologic…
- Conditions
- Bloodstream Infection, Gram Negative Infections, Bacteraemia Caused by Gram-Negative Bacteria, Febrile Neutropenia (FN)
- Trial name
- PERaSTrA (NCT07372131)
- Testing
- Clinical Stability-Driven Antibiotic Discontinuation Strategy, Standard of Care Antibiotic Duration
- Where
- Italy
- Volunteers
- 172 people
- Sponsor
- Valeria Cento
Pediatric Malignant Solid Tumor, Febrile Neutropenia (FN)
Phase II Study of QLC2519 in Pediatric Solid Tumor Participants
QLC2519 (Mai Li Sheng®) is a new protein drug created by fusing the N-terminal of highly active modified G-CSF with the C-terminal of HSA.
- Conditions
- Pediatric Malignant Solid Tumor, Febrile Neutropenia (FN), Neutropenia
- Trial name
- NCT07724756
- Testing
- Albipagrastim alf
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Febrile Neutropenia (FN), Pediatric Cancer
Early Discontinuation of Antibiotics in Paediatric High-risk Febrile Neutropenia
The goal of this clinical trial is to evaluate whether stopping antibiotic treatment early is safe in paediatric patients with cancer who develop high-risk febrile neutropenia but show good clinical evolution and low biomarker…
- Conditions
- Febrile Neutropenia (FN), Pediatric Cancer, Hematologic Malignancies, Solid Tumors
- Trial name
- E-STOP2 (NCT07590648)
- Testing
- Early Discontinuation of Antibiotics, Standard Antibiotic Continuation Strategy
- Where
- 4 sites in Spain
- Volunteers
- 136 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Non-Hodgkin's Lymphoma (NHL), Granulocyte Colony Stimulating Factor
Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients
The goal of this clinical trial is to Primary Objectives: 1. To compare the incidence of febrile neutropenia in patients with non-Hodgkin's lymphoma who received early or late granulocyte colony-stimulating factor (G-CSF) during…
- Conditions
- Non-Hodgkin's Lymphoma (NHL), Granulocyte Colony Stimulating Factor, Febrile Neutropenia (FN), Myelosuppression Adult
- Trial name
- G-CSF in NHL (NCT06665737)
- Testing
- Early receiving G-CSF group, Late receiving G-CSF group
- Where
- 3 sites in Thailand
- Volunteers
- 126 people
- Sponsor
- Department of Medical Services Ministry of Public Health of Thailand